Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men
Marie-Pierre St-Onge, Robert Ross, William D Parsons, Peter J H Jones, Marie-Pierre St-Onge, Robert Ross, William D Parsons, Peter J H Jones
Abstract
Objective: The objectives of this study were to compare the effects of diets rich in medium-chain triglycerides (MCTs) or long-chain triglycerides (LCTs) on body composition, energy expenditure, substrate oxidation, subjective appetite, and ad libitum energy intake in overweight men.
Research methods and procedures: Twenty-four healthy, overweight men with body mass indexes between 25 and 31 kg/m(2) consumed diets rich in MCT or LCT for 28 days each in a crossover randomized controlled trial. At baseline and after 4 weeks of each dietary intervention, energy expenditure was measured using indirect calorimetry, and body composition was analyzed using magnetic resonance imaging.
Results: Upper body adipose tissue (AT) decreased to a greater extent (p < 0.05) with functional oil (FctO) compared with olive oil (OL) consumption (-0.67 +/- 0.26 kg and -0.02 +/- 0.19 kg, respectively). There was a trend toward greater loss of whole-body subcutaneous AT volume (p = 0.087) with FctO compared with OL consumption. Average energy expenditure was 0.04 +/- 0.02 kcal/min greater (p < 0.05) on day 2 and 0.03 +/- 0.02 kcal/min (not significant) on day 28 with FctO compared with OL consumption. Similarly, average fat oxidation was greater (p = 0.052) with FctO compared with OL intake on day 2 but not day 28.
Discussion: Consumption of a diet rich in MCTs results in greater loss of AT compared with LCTs, perhaps due to increased energy expenditure and fat oxidation observed with MCT intake. Thus, MCTs may be considered as agents that aid in the prevention of obesity or potentially stimulate weight loss.
Source: PubMed
今後の臨床試験
-
AstraZenecaまだ募集していません
-
Shenyang Sunshine Pharmaceutical Co., LTD.募集局所進行性(切除不能)または転移性固形腫瘍中国
-
The First Affiliated Hospital with Nanjing Medical...募集
-
Stanford Universityまだ募集していません
-
Takedaまだ募集していません特発性過眠症 | ナルコレプシー1型 | ナルコレプシー2型
-
Imperial College Londonまだ募集していません
-
Lifetech Scientific (Shenzhen) Co., Ltd.募集
-
Tongji Hospital募集術後合併症 | 胸部外科 | Perioperative Monitoring中国
-
Longevity Metrics, Inc.募集心血管疾患 | 新生物 | 死亡 | 職業病 | 認知機能障害 | メタボリック・シンドローム | 認知症 | もろさ | エージング | 筋骨格疾患 | 日常生活の行動 | 環境暴露 | 身体障害者 | 健康の社会的決定要因 | 神経変性疾患 | 健康関連の生活の質 | 健康の公平性 | 全死亡率 | Life Expectancyアメリカ
-
Saveetha Universityまだ募集していません
-
M.D. Anderson Cancer CenterPharmaEssentiaまだ募集していませんアザシチジン | MDS/AML | Ropeginterferon | Alfa-2bアメリカ